CD147 expression is associated with poor overall survival in chemotherapy treated triple-negative breast cancer
Publication in refereed journal

Times Cited
Altmetrics Information

Other information
In breast cancer models, the functional roles of CD147 in proliferation, invasion and treatment resistance have been widely reported. However, there are only a few studies examining the clinicopathological correlation and prognostic relevance of CD147 in breast cancer, especially in relation to breast cancer molecular subtypes.

In this study, we analysed CD147 expression in a large cohort of breast cancers, correlating with clinicopathological features and the expression of a comprehensive panel of biomarkers in triple-negative breast cancer (TNBC) and non-TNBC subsets. Its relationship with patients' survival was also analysed.

CD147 was expressed in 11.9%(140/1174) of all cases and in 23.8% (40/168) of TNBC. The expression was associated with tumour histological subtypes (p=0.01) and most commonly seen in carcinoma with medullary features (26.0%). CD147 expression correlated with high tumour grade, presence of necrosis and basal-like breast cancer (BLBC) subtype, high Ki67 and expression of some other basal markers and stem-like markers. CD147 expression was also associated with poor overall survival in chemotherapy treated patients with TNBC.

CD147 is a putative marker in identifying TNBC or BLBC, and may be useful as a prognosis indicator for patients with TNBC or BLBC post chemotherapy.
All Author(s) ListMing Liu, Julia Y S Tsang, Michelle Lee, Yun-Bi Ni, Siu-Ki Chan, Sai-Yin Cheung, Jintao Hu, Hong Hu, Gary M K Tse
Journal nameJournal of Clinical Pathology
Volume Number71
Issue Number11
Pages1007 - 1014
LanguagesEnglish-United Kingdom

Last updated on 2021-01-12 at 23:33